RT Journal Article
SR Electronic
T1 Assessing Relative Coronavirus Disease 2019 Mortality: A Swiss Population-based Study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.06.10.20127670
DO 10.1101/2020.06.10.20127670
A1 Hothorn, Torsten
A1 Bopp, Matthias
A1 Günthard, Huldrych F.
A1 Keiser, Olivia
A1 Roelens, Maroussia
A1 Weibull, Caroline E.
A1 Crowther, Michael J.
YR 2020
UL http://medrxiv.org/content/early/2020/10/21/2020.06.10.20127670.abstract
AB Objective Severity of the coronavirus disease 2019 (covid-19) has been previously reported in terms of absolute mortality in SARS-CoV-2 positive cohorts. An assessment of mortality relative to mortality in the general population is presented.Design Retrospective population-based study.Setting Individual information on symptomatic confirmed SARS-CoV-2 patients and subsequent deaths from any cause were compared to the all-cause mortality in the Swiss population of 2018. Starting February 23, 2020, mortality in covid-19 patients was monitored for 80 days and compared to the population mortality observed in the same time-of-year starting February 23, 2018.Participants 5 169 071 inhabitants of Switzerland aged 35 to 95 without covid-19 (general population in spring 2018) and 20 769 persons tested positively for covid-19 during the first wave in spring 2020.Measurements Sex- and age-specific mortality rates were estimated using Cox proportional hazards models. Absolute probabilities of death were predicted and risk was assessed in terms of relative mortality by taking the ratio between the sex- and age-specific absolute mortality in covid-19 patients and the corresponding mortality in the 2018 general population.Results Absolute mortalities increased with age and were higher for males compared to females, both in the general population and in positively tested persons. A confirmed SARS-CoV-2 infection substantially increased the probability of death across all patient groups at least nine-fold. The highest relative risks were observed among males and younger patients. Male covid-19 patients exceeded the population hazard for males (hazard ratio 1.23, 1.03 to 1.47). An additional year of age increased the population hazard in covid-19 patients only marginally (hazard ratio 1.01, 1.00 to 1.02).Conclusions Health care professionals, decision makers, and societies are provided with an additional population-adjusted assessment of covid-19 mortality risk. In combination with absolute measures of risk, the relative risks presented here help to develop a more comprehensive understanding of the actual impact of covid-19.Strengths and limitations of this studyAn assessment of covid-19 risk in terms of relative mortality rates comparing a cohort of symptomatic and confirmed covid-19 patients to the general population is provided.Relative mortality for quantifying sex- and age-specific covid-19 risk is unaffected by seasonal effects, cause of death (covid-19 related or not), impact of public health interventions, or testing coverage.The study excluded patients younger than 35 years and older than 95 years, as well as patients tested posthumously or after having been admitted to a hospital for reasons other than covid-19.Information about the distribution of relevant comorbidities was not available on population level and the associated risk was not quantified.Differential covid-19 risk for relevant patient subpopulations, such as pregnant women, low-income residents, ethnic or cultural minorities, was not assessed.Competing Interest StatementTH has been paid for consulting, lectures or presentations from Novartis, Roche, and PricewaterhouseCoopers. HFG has received unrestricted research grants from Gilead Sciences and Roche; fees for data and safety monitoring board membership from Merck; consulting/advisory board membership fees from Gilead Sciences, Merck and ViiV Healthcare; and grants from SystemsX, and the National Institutes of Health. MJC has been paid for consulting, lectures or presentations from Roche and Reinsurance Group of America UK Services Limited.Funding StatementSwiss National Science Foundation. The funder of this study had no role in study design, data collection, data analysis, data interpretation, or writing of the final report.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:not applicableAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll results can be reproduced from study cohorts, R and Stata computer code publically available from https://gitlab.switch.ch/torsten.hothorn/relative_covid-19_mortality https://gitlab.switch.ch/torsten.hothorn/relative_covid-19_mortality